{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:01:40Z","timestamp":1768838500397,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["Preludium\/2015\/17\/N\/NZ7\/04107"],"award-info":[{"award-number":["Preludium\/2015\/17\/N\/NZ7\/04107"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical and experimental cancer therapy is multifaceted; one such facet is the use of drug carriers. Drug carriers are various nano- and macromolecules, e.g., oligosaccharides, proteins, and liposomes. The present study aimed to verify the suitability of cellulose as a carrier for methotrexate (MTX). Hydroxyethylcellulose, with a molecular weight of 90\u00a0kDa and soluble in water, was used. Methotrexate was linked to cellulose by methyl ester bonds. A conjugate containing on average 9.5 molecules of MTX per molecule of cellulose was developed. Gel filtration HPLC analysis showed that the conjugate contained approximately 2% free drug. Dynamic light scattering analysis showed an increase in the polydispersity of the conjugate. The degradation of the conjugate in phosphate buffer and plasma followed first-order kinetics. The conjugate showed the lowest stability (half-life 154\u00a0h) in plasma. The conjugate showed 10-fold lower cytotoxicity to the 4\u00a0T1 mammary tumour cell line than the free drug. In the in vivo experiment to treat orthotopically implanted mammary tumours, the conjugate and the free drug, both applied intravenously, showed maximum inhibition of tumour growth of 48.4% and 11.2%, respectively. In conclusion, cellulose, which is a non-biodegradable chain glucose polymer, can be successfully used as a drug carrier, which opens up new research perspectives.<\/jats:p>","DOI":"10.1007\/s10637-020-00972-9","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T16:03:36Z","timestamp":1594224216000},"page":"15-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hydroxyethylcellulose as a methotrexate carrier in anticancer therapy"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-2338","authenticated-orcid":false,"given":"Jaros\u0142aw","family":"Ciekot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Psurski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Jurec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Boraty\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"972_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.suronc.2010.02.002","volume":"21","author":"RL Elliott","year":"2012","unstructured":"Elliott RL (2012) Combination cancer immunotherapy \"expanding Paul Ehrlich's magic bullet concept\". Surg Oncol 21:53\u201355. https:\/\/doi.org\/10.1016\/j.suronc.2010.02.002","journal-title":"Surg Oncol"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","volume":"18","author":"I Ekladious","year":"2019","unstructured":"Ekladious I, Colson YL, Grinstaff MW (2019) Polymer-drug conjugate therapeutics: advances, insights and prospects. Nat Rev Drug Discov 18:273\u2013294. https:\/\/doi.org\/10.1038\/s41573-018-0005-0","journal-title":"Nat Rev Drug Discov"},{"key":"972_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.msec.2019.01.095","volume":"99","author":"FJ Chaparro","year":"2019","unstructured":"Chaparro FJ, Presley KF, Coutinho da Silva MA, Lannutti JJ (2019) Sintered electrospun polycaprolactone for controlled model drug delivery. Mater Sci Eng C Mater Biol Appl 99:112\u2013120. https:\/\/doi.org\/10.1016\/j.msec.2019.01.095","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/bc00017a001","volume":"3","author":"H Maeda","year":"1992","unstructured":"Maeda H, Seymour LW, Miyamoto Y (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3:351\u2013362. https:\/\/doi.org\/10.1021\/bc00017a001","journal-title":"Bioconjug Chem"},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2217\/nnm.16.33","volume":"11","author":"KM Camacho","year":"2016","unstructured":"Camacho KM, Menegatti S, Mitragotri S (2016) Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations. Nanomedicine (Lond) 11:1139\u20131151. https:\/\/doi.org\/10.2217\/nnm.16.33","journal-title":"Nanomedicine (Lond)"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1023\/a:1016489002393","volume":"4","author":"Y Takakura","year":"1987","unstructured":"Takakura Y, Takagi A, Hashida M, Sezaki H (1987) Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm Res 4:293\u2013300. https:\/\/doi.org\/10.1023\/a:1016489002393","journal-title":"Pharm Res"},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y (2012) Doxil\u00ae--the first FDA-approved nano-drug: lessons learned. J Control Release 160:117\u2013134. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020","journal-title":"J Control Release"},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2013.02.026","volume":"168","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Alakhova DY, Kim JO, Bronich TK, Kabanov AV (2013) A simple way to enhance Doxil\u00ae therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release 168:61\u201369. https:\/\/doi.org\/10.1016\/j.jconrel.2013.02.026","journal-title":"J Control Release"},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","volume":"10","author":"H Kaplon","year":"2018","unstructured":"Kaplon H, Reichert JM (2018) Antibodies to watch in 2018. MAbs 10:183\u2013203. https:\/\/doi.org\/10.1080\/19420862.2018.1415671","journal-title":"MAbs"},{"key":"972_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK (2018) Monoclonal antibodies: a review. Curr Clin Pharmacol 13:85\u201399. https:\/\/doi.org\/10.2174\/1574884712666170809124728","journal-title":"Curr Clin Pharmacol"},{"key":"972_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.47","volume":"2","author":"TM Goszczy\u0144ski","year":"2014","unstructured":"Goszczy\u0144ski TM, Filip-Psurska B, Kempi\u0144ska K, Wietrzyk J, Boraty\u0144ski J (2014) Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy. Pharmacol Res Perspect 2:e00047. https:\/\/doi.org\/10.1002\/prp2.47","journal-title":"Pharmacol Res Perspect"},{"key":"972_CR12","first-page":"1135","volume":"26","author":"D Nevozhay","year":"2006","unstructured":"Nevozhay D, Budzynska R, Kanska U, Jagiello M, Omar MS, Boratynski J, Opolski A (2006) Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier. Anticancer Res 26:1135\u20131143","journal-title":"Anticancer Res"},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"417672","DOI":"10.1155\/2013\/417672","volume":"2013","author":"I Cumpstey","year":"2013","unstructured":"Cumpstey I (2013) Chemical modification of polysaccharides. ISRN Org Chem 2013:417672\u2013417627. https:\/\/doi.org\/10.1155\/2013\/417672","journal-title":"ISRN Org Chem"},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1556-276x-9-247","volume":"9","author":"E Abbasi","year":"2014","unstructured":"Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, Hanifehpour Y, Nejati-Koshki K, Pashaei-Asl R (2014) Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett 9:247. https:\/\/doi.org\/10.1186\/1556-276x-9-247","journal-title":"Nanoscale Res Lett"},{"key":"972_CR15","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1021\/bm401593n","volume":"15","author":"S Dong","year":"2014","unstructured":"Dong S, Cho HJ, Lee YW, Roman M (2014) Synthesis and cellular uptake of folic acid-conjugated cellulose nanocrystals for cancer targeting. Biomacromolecules 15:1560\u20131567. https:\/\/doi.org\/10.1021\/bm401593n","journal-title":"Biomacromolecules"},{"key":"972_CR16","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1039\/c6nr09494e","volume":"9","author":"D Trache","year":"2017","unstructured":"Trache D, Hussin MH, Haafiz MK, Thakur VK (2017) Recent progress in cellulose nanocrystals: sources and production. Nanoscale 9:1763\u20131786. https:\/\/doi.org\/10.1039\/c6nr09494e","journal-title":"Nanoscale"},{"key":"972_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.carbpol.2012.06.012","volume":"90","author":"AM Eissa","year":"2012","unstructured":"Eissa AM, Khosravi E, Cimecioglu AL (2012) A versatile method for functionalization and grafting of 2-hydroxyethyl cellulose (HEC) via click chemistry. Carbohydr Polym 90:859\u2013869. https:\/\/doi.org\/10.1016\/j.carbpol.2012.06.012","journal-title":"Carbohydr Polym"},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.beha.2009.09.004","volume":"22","author":"JR Bertino","year":"2009","unstructured":"Bertino JR (2009) Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol 22:577\u2013582. https:\/\/doi.org\/10.1016\/j.beha.2009.09.004","journal-title":"Best Pract Res Clin Haematol"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/jci112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907\u2013912. https:\/\/doi.org\/10.1172\/jci112088","journal-title":"J Clin Invest"},{"key":"972_CR20","first-page":"1342","volume":"69","author":"J Ciekot","year":"2012","unstructured":"Ciekot J, Goszczy\u0144ski T, Boraty\u0144skit J (2012) Methods for methotrexate determination in macromolecular conjugates drug carrier. Acta Pol Pharm 69:1342\u20131346","journal-title":"Acta Pol Pharm"},{"key":"972_CR21","doi-asserted-by":"publisher","first-page":"27191","DOI":"10.3390\/ijms161126016","volume":"16","author":"E Maj","year":"2015","unstructured":"Maj E, Filip-Psurska B, \u015awitalska M, Kutner A, Wietrzyk J (2015) Vitamin D analogs potentiate the antitumor effect of imatinib mesylate in a human A549 lung tumor model. Int J Mol Sci 16:27191\u201327207. https:\/\/doi.org\/10.3390\/ijms161126016","journal-title":"Int J Mol Sci"},{"key":"972_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106186","volume":"9","author":"D Nevozhay","year":"2014","unstructured":"Nevozhay D (2014) Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays. PLoS One 9:e106186. https:\/\/doi.org\/10.1371\/journal.pone.0106186","journal-title":"PLoS One"},{"key":"972_CR23","first-page":"539","volume":"27","author":"RW Heinle","year":"1948","unstructured":"Heinle RW, Welch AD (1948) Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. J Clin Invest 27:539","journal-title":"J Clin Invest"},{"key":"972_CR24","first-page":"38","volume":"18","author":"D Nevozhay","year":"2007","unstructured":"Nevozhay D, Budzynska R, Kanska U, Wietrzyk J, Boratynski J (2007) Improved antileukemic effect of methotrexate coupled with dextran in mouse model of leukemia. Ann Oncol 18:38","journal-title":"Ann Oncol"},{"key":"972_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0304-3835(99)00334-1","volume":"148","author":"J Boraty\u0144ski","year":"2000","unstructured":"Boraty\u0144ski J, Opolski A, Wietrzyk J, G\u00f3rski A, Radzikowski C (2000) Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate. Cancer Lett 148:189\u2013195. https:\/\/doi.org\/10.1016\/S0304-3835(99)00334-1","journal-title":"Cancer Lett"},{"key":"972_CR26","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.3390\/ijms12074591","volume":"12","author":"A Taheri","year":"2011","unstructured":"Taheri A, Dinarvand R, Atyabi F, Ahadi F, Nouri FS, Ghahremani MH, Ostad SN, Borougeni AT, Mansoori P (2011) Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide. Int J Mol Sci 12:4591\u20134608. https:\/\/doi.org\/10.3390\/ijms12074591","journal-title":"Int J Mol Sci"},{"key":"972_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.addr.2012.08.012","volume":"65","author":"R Duncan","year":"2013","unstructured":"Duncan R, Vicent MJ (2013) Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 65:60\u201370. https:\/\/doi.org\/10.1016\/j.addr.2012.08.012","journal-title":"Adv Drug Deliv Rev"},{"key":"972_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.copbio.2011.05.507","volume":"22","author":"R Duncan","year":"2011","unstructured":"Duncan R (2011) Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 22:492\u2013501. https:\/\/doi.org\/10.1016\/j.copbio.2011.05.507","journal-title":"Curr Opin Biotechnol"},{"key":"972_CR29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrc1958","volume":"6","author":"R Duncan","year":"2006","unstructured":"Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688\u2013701. https:\/\/doi.org\/10.1038\/nrc1958","journal-title":"Nat Rev Cancer"},{"key":"972_CR30","doi-asserted-by":"publisher","unstructured":"Janaszewska A, Lazniewska J, Trzepi\u0144ski P, Marcinkowska M, Klajnert-Maculewicz B (2019) Cytotoxicity of dendrimers. Biomolecules 9. https:\/\/doi.org\/10.3390\/biom9080330","DOI":"10.3390\/biom9080330"},{"key":"972_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/bc100070g","volume":"21","author":"H Maeda","year":"2010","unstructured":"Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 21:797\u2013802. https:\/\/doi.org\/10.1021\/bc100070g","journal-title":"Bioconjug Chem"},{"key":"972_CR32","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/polym6082186","volume":"6","author":"A Rajora","year":"2014","unstructured":"Rajora A, Ravishankar D, Osborn H, Greco F (2014) Impact of the enhanced permeability and retention (EPR) effect and cathepsins levels on the activity of polymer-drug conjugates. Polymers 6:2186\u20132220. https:\/\/doi.org\/10.3390\/polym6082186","journal-title":"Polymers"},{"key":"972_CR33","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3109\/03639045.2014.954582","volume":"41","author":"H Shibata","year":"2015","unstructured":"Shibata H, Izutsu K, Yomota C, Okuda H, Goda Y (2015) Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions. Drug Dev Ind Pharm 41:1376\u20131386. https:\/\/doi.org\/10.3109\/03639045.2014.954582","journal-title":"Drug Dev Ind Pharm"},{"key":"972_CR34","first-page":"6831","volume":"62","author":"RB Campbell","year":"2002","unstructured":"Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831\u20136836","journal-title":"Cancer Res"},{"key":"972_CR35","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.bbagen.2012.11.005","volume":"1830","author":"T Goszczy\u0144ski","year":"2013","unstructured":"Goszczy\u0144ski T, Nevozhay D, Wietrzyk J, Omar MS, Boraty\u0144ski J (2013) The antileukemic activity of modified fibrinogen\u2013methotrexate conjugate. Biochim Biophys Acta 1830:2526\u20132530. https:\/\/doi.org\/10.1016\/j.bbagen.2012.11.005","journal-title":"Biochim Biophys Acta"},{"key":"972_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s11095-008-9746-5","volume":"26","author":"C-S Chen","year":"2009","unstructured":"Chen C-S, Ofner CM (2009) The effect of molecular weight, drug load, and charge of gelatin\u2013MTX conjugates on growth inhibition of HL-60 leukemia cells. Pharm Res 26:338\u2013345. https:\/\/doi.org\/10.1007\/s11095-008-9746-5","journal-title":"Pharm Res"},{"key":"972_CR37","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1016\/j.bmc.2009.04.063","volume":"17","author":"A Homma","year":"2009","unstructured":"Homma A, Sato H, Okamachi A, Emura T, Ishizawa T, Kato T, Matsuura T, Sato S, Tamura T, Higuchi Y, Watanabe T, Kitamura H, Asanuma K, Yamazaki T, Ikemi M, Kitagawa H, Morikawa T, Ikeya H, Maeda K, Takahashi K, Nohmi K, Izutani N, Kanda M, Suzuki R (2009) Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Bioorg Med Chem 17:4647\u20134656. https:\/\/doi.org\/10.1016\/j.bmc.2009.04.063","journal-title":"Bioorg Med Chem"},{"key":"972_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1751-553X.2007.00936.x","volume":"30","author":"X Wang","year":"2008","unstructured":"Wang X, Yao C, Jiang Z (2008) Conjugation of methotrexate to immunoglobulins kills macrophages by fc receptor mediated uptake? Int J Lab Hematol 30:185\u2013190. https:\/\/doi.org\/10.1111\/j.1751-553X.2007.00936.x","journal-title":"Int J Lab Hematol"},{"key":"972_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijpharm.2012.04.033","volume":"431","author":"A Taheri","year":"2012","unstructured":"Taheri A, Dinarvand R, Ahadi F, Khorramizadeh MR, Atyabi F (2012) The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb\/c mice. Int J Pharm 431:183\u2013189. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.033","journal-title":"Int J Pharm"},{"key":"972_CR40","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2147\/ijn.s23949","volume":"6","author":"A Taheri","year":"2011","unstructured":"Taheri A, Dinarvand R, Nouri FS, Khorramizadeh MR, Borougeni AT, Mansoori P, Atyabi F (2011) Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int J Nanomedicine 6:1863\u20131874. https:\/\/doi.org\/10.2147\/ijn.s23949","journal-title":"Int J Nanomedicine"},{"key":"972_CR41","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1021\/mp400643p","volume":"11","author":"A Roy","year":"2014","unstructured":"Roy A, Murakami M, Ernsting MJ, Hoang B, Undzys E, Li SD (2014) Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance. Mol Pharm 11:2592\u20132599. https:\/\/doi.org\/10.1021\/mp400643p","journal-title":"Mol Pharm"},{"key":"972_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/nsa.s64386","volume":"8","author":"J George","year":"2015","unstructured":"George J, Sabapathi SN (2015) Cellulose nanocrystals: synthesis, functional properties, and applications. Nanotechnol Sci Appl 8:45\u201354. https:\/\/doi.org\/10.2147\/nsa.s64386","journal-title":"Nanotechnol Sci Appl"},{"key":"972_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/jipb.12349","volume":"57","author":"S Andersson","year":"2015","unstructured":"Andersson S, Wang Y, P\u00f6nni R, H\u00e4nninen T, Mononen M, Ren H, Serimaa R, Saranp\u00e4\u00e4 P (2015) Cellulose structure and lignin distribution in normal and compression wood of the maidenhair tree (Ginkgo biloba L.). J Integr Plant Biol 57:388\u2013395. https:\/\/doi.org\/10.1111\/jipb.12349","journal-title":"J Integr Plant Biol"},{"key":"972_CR44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1021\/ar900035f","volume":"42","author":"ME Fox","year":"2009","unstructured":"Fox ME, Szoka FC, Fr\u00e9chet JM (2009) Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res 42:1141\u20131151. https:\/\/doi.org\/10.1021\/ar900035f","journal-title":"Acc Chem Res"},{"key":"972_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2009.05.021","volume":"140","author":"B Chen","year":"2009","unstructured":"Chen B, Jerger K, Fr\u00e9chet JM, Szoka FC Jr (2009) The influence of polymer topology on pharmacokinetics: differences between cyclic and linear PEGylated poly(acrylic acid) comb polymers. J Control Release 140:203\u2013209. https:\/\/doi.org\/10.1016\/j.jconrel.2009.05.021","journal-title":"J Control Release"},{"key":"972_CR46","first-page":"16","volume":"124","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16\u201325","journal-title":"Trans Am Clin Climatol Assoc"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00972-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00972-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00972-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:53:01Z","timestamp":1678510381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00972-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00972-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jaros\u0142aw Ciekot declares no conflict of interest. Mateusz Psurski declares no conflict of interest. Katarzyna Jurec declares no conflict of interest. Janusz Boraty\u0144ski declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. All applicable international and national guidelines for the care and use of animals were followed. Research on experimental animals was carried out with the consent of the local ethics committee for animal experiments (number 85\/2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}}]}}